Preliminary results suggest that targeting B7-H3+ tumors, including highly aggressive malignancies such as diffuse intrinsic pontine glioma (DIPG), is feasible, associated with manageable toxicities, and capable of achieving durable tumor regression in some patients6. The gene discussed is CD276; the disease is neoplasm.